Navigation Links
VIVUS to Present at Two Upcoming Investor Conferences
Date:3/3/2010

lable on VIVUS' website at http://www.vivus.com.

About VIVUS

VIVUS is a biopharmaceutical company developing innovative, next- generation therapies to address unmet needs in obesity, sleep apnea, diabetes and sexual health. The company's lead product in clinical development, Qnexa(R), has completed phase 3 clinical trials for the treatment of obesity and an NDA has been filed and accepted by the FDA, with an action date of October 28, 2010. Qnexa is also in phase 2 clinical development for the treatment of type 2 diabetes and obstructive sleep apnea. In the area of sexual health, VIVUS is in phase 3 development with avanafil, a potentially best-in-class PDE5 inhibitor for the treatment of erectile dysfunction, and in phase 2 development of Luramist(TM) for the treatment of hypoactive sexual desire disorder (HSDD) in women. MUSE(R) (alprostadil), a first generation therapy for the treatment of ED, is already on the market and generating revenue for VIVUS. For more information about the company, please visit www.vivus.com.

    CONTACT:

    VIVUS, Inc.
    Timothy E. Morris
    Chief F
'/>"/>
SOURCE VIVUS, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. VIVUS Reports Third Quarter 2009 Highlights and Financial Results
2. VIVUS Announces Positive Results From Two Phase 3 Studies; Obese Patients on Qnexa Achieve Average Weight Loss up to 14.7% and Significant Improvements in Co-Morbidities
3. VIVUS to Present at Four Upcoming Healthcare Conferences
4. VIVUS to Present at the Canaccord Adams 29th Annual Global Growth Conference
5. VIVUS to Present at the Needham and Company Life Sciences Conference
6. Data on VIVUS Qnexa To Be Presented During Two Podium Presentations at ADA Annual Meeting
7. VIVUS Reports First Quarter 2009 Financial Results and Highlights
8. PDI to Present at the ROTH Capital Partners 22nd Annual OC Growth Stock Conference
9. Nutrastar International, Inc. to Present at the 2010 Rodman & Renshaw Annual China Investment Conference in Beijing
10. OncoGenex Pharmaceuticals to Present at RBC Capital Markets Healthcare Conference
11. Creating a Better Health Ecosystem Focus of Presentation by Aleres Dr. Gordon Norman at Population Health & Disease Management Colloquium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... August 27, 2014 Budding Biomedical ... University School participated in the Scientific ... Reserve University’s School of Medicine . ... an unparalleled professional experience in the sciences and ... Medicine faculty and students for both academic and ...
(Date:8/26/2014)... The 20 ambassadors representing the ALS Therapy Development ... following statement on Facebook today regarding the global Ice ... specifically for ALS research: , “Who would have thought ... raise all this awareness and funding toward ALS research! ... of the entire ALS community, would like to express ...
(Date:8/26/2014)... 26, 2014  ViveBio, LLC a leading provider ... and transportation, announced today that it has signed ... (LPS) of Knoxville, Tennessee ... the United States . ViveST is ... temperature dried biological specimen transport systems.  The technology ...
(Date:8/26/2014)... (PRWEB) August 26, 2014 Genedata, ... drug discovery and life science research, today announced ... will be held in Asia, Europe, and ... global pharmaceutical companies and leading research organizations will ... best practices, case studies, and upcoming challenges in ...
Breaking Biology Technology:Students at Cleveland's University School Conduct Biomedical Research at Case Western Reserve University’s School of Medicine 2ALS TDI’s Young Faces of ALS Ambassadors Thank You for Accepting the Ice Bucket Challenge to End ALS 2ALS TDI’s Young Faces of ALS Ambassadors Thank You for Accepting the Ice Bucket Challenge to End ALS 3ALS TDI’s Young Faces of ALS Ambassadors Thank You for Accepting the Ice Bucket Challenge to End ALS 4ViveBio and Laboratory Procurement Services Sign Agreement for Distribution of the ViveST Line of Products 2Thought Leaders to Explore Innovations in SPR & Combination Screening at Genedata Screener User Group Meetings 2Thought Leaders to Explore Innovations in SPR & Combination Screening at Genedata Screener User Group Meetings 3
... 21 CV Therapeutics,Inc. (Nasdaq: CVTX ) announced ... been accepted for presentation at the American,College of Cardiology ... Chicago, IL on March 29 - April 1, 2008., ... Activity in Isolated Rat Left Atrial,Appendage; Poster; Sunday, March ...
... Biopharmaceuticals,Inc. (Nasdaq: KERX ) will hold a conference ... to discuss the fourth quarter and year-end 2007,financial results ... Chief Executive Officer of the Company, will host the ... in a press release to be,issued prior to the ...
... PDL BioPharma Have Entered into an Agreement Under, Which Genmab ... ... Minnesota, USA, COPENHAGEN, Denmark and REDWOOD CITY, California, February ... PDLI ) announced today that they have entered into an ...
Cached Biology Technology:CV Therapeutics Announces Presentations at the American College of Cardiology 57th Annual Scientific Session 2CV Therapeutics Announces Presentations at the American College of Cardiology 57th Annual Scientific Session 3Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year-End 2007 Financial Results on Monday, February 25, at 8:30 A.M. EST 2Genmab and PDL BioPharma Sign Purchase Agreement for Antibody Manufacturing Facility 2Genmab and PDL BioPharma Sign Purchase Agreement for Antibody Manufacturing Facility 3Genmab and PDL BioPharma Sign Purchase Agreement for Antibody Manufacturing Facility 4Genmab and PDL BioPharma Sign Purchase Agreement for Antibody Manufacturing Facility 5
(Date:8/26/2014)... the University of Liverpool has recommended investing in dog owner ... and problems such as obesity in both people and their ... 1990, the researchers found that access to dog-friendly walking environments ... people to get out and take more exercise with their ... don,t take their dogs for a walk. In the UK, ...
(Date:8/25/2014)... biofuels industry: "You can make anything from lignin ... pave the way to challenging that adage. The ... Laboratory (NREL) demonstrates a concept that provides opportunities ... variety of renewable fuels, chemicals, and materials for ... Through Integrated Biological Funneling and Chemical Catalysis " ...
(Date:8/25/2014)... of proteins that promotes virus entry into cells also ... and other viruses, University of Missouri researchers have found. ... insights into our understanding of not only HIV infection, ... Shan-Lu Liu, M.D., Ph.D., associate professor in the MU ... , The study was recently published in the ...
Breaking Biology News(10 mins):Education and dog-friendly neighbourhoods could tackle obesity 2New process helps overcome obstacles to produce renewable fuels and chemicals 2MU researchers discover protein's ability to inhibit HIV release 2MU researchers discover protein's ability to inhibit HIV release 3
... Researchers are still fascinated by the idea of the ... them into cells with the capacity to differentiate into ... are still striving to understand how it happens. ... (CNIO), headed by researcher Ralph P. Schneider, from the ...
... A new study finds that utilities aren,t rewarded for ... to make energy efficiency as attractive as renewables. ... Environmental Law , examines key differences between energy ... assistant professor at Oregon State University, outlines ways to ...
... a private company focused on the development of targeted ... has entered into a license agreement with the Spanish ... rights to develop and commercialise several novel kinase inhibitors ... CNIO,s considerable expertise in drug discovery and comprise a ...
Cached Biology News:CNIO researchers identify a new gene that is essential for nuclear reprogramming 2Study finds disincentives to energy efficiency can be fixed 2